European guidelines on managing adverse effects of medication for ADHD.
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor ad...
| Publicado en: | European Child & Adolescent Psychiatry Vol. 20; no. 1; pp. 17 - 38 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jan2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104971799&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104971799 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10188827 EJ3 jtl: European Child & Adolescent Psychiatry issn: 10188827 maglogo: N pubinfo: dt: Jan2011 vid: 20 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104971799 2010892605 10.1007/s00787-010-0140-6 NLM21042924 PMC3012210 104971799 ppf: 17 ppct: 21 formats: fmt: @attributes: type: P tig: atl: European guidelines on managing adverse effects of medication for ADHD. aug: au: Graham J Banaschewski T Buitelaar J Coghill D Danckaerts M Dittmann R Döpfner M Hamilton R Hollis C Holtmann M Hulpke-Wette M Lecendreux M Rosenthal E Rothenberger A Santosh P Sergeant J Simonoff E Sonuga-Barke E Wong I Zuddas A sug: subj: Attention Deficit Hyperactivity Disorder Drug Therapy Practice Guidelines Drug Administration Standards Central Nervous System Stimulants Therapeutic Use Central Nervous System Stimulants Adverse Effects Risk Management Cardiovascular Risk Factors Child Europe Suicide Risk Factors Hypertension Risk Factors Psychotic Disorders Risk Factors Child: 6-12 years ab: The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|